Company profile: IMGM Laboratories
1.1 - Company Overview
Company description
- Provider of advanced genomic services via a service center in Martinsried, Germany for academic and industrial genome research, serving pharma, diagnostics, academia and biotech. Accredited to DIN EN ISO/IEC 17025 for gene expression analysis using Agilent microarrays and qPCR, and offering first-class NGS, metagenomic sequencing, biomarker discovery, pharmacogenetics, and qPCR/ddPCR-based biodistribution studies.
Products and services
- Biomarker Discovery: Architects biomarker panels for trait or disease association and personalized medicine by executing sample processing and bioinformatics analysis within a DIN EN ISO/IEC 17025-accredited framework
- Metagenomic Sequencing: Engineers high-throughput NGS-based analyses to identify microbial composition across diverse environments, elucidating microorganism roles within complex communities through comprehensive profiling
- Biodistribution Studies: Develops and validates qPCR/ddPCR-based study designs to evaluate safety and toxicity of nucleic acid therapeutics in pre-clinical settings, ensuring robust quantification and detection
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to IMGM Laboratories
Foresight Diagnostics
HQ: United States
Website
- Description: Provider of liquid biopsy-based cancer detection and monitoring solutions leveraging patient-specific phased variants, including Foresight CLARITY MRD assays for lymphoma and solid tumors; the PhasED-Seq high-sensitivity ctDNA test; MRD-driven clinical trials; a ctDNA research assay to quantify and monitor disease burden; and customizable SNV and CNV genotyping.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Foresight Diagnostics company profile →
Locus Biosciences
HQ: United States
Website
- Description: Provider of CRISPR-engineered precision antibacterial therapies using bacteriophages. Portfolio includes LBP-EC01 for E. coli urinary tract infections; LBP-PA01 and LBP-SA01 targeting P. aeruginosa and S. aureus with Janssen; and LBP-KP01 for K. pneumoniae supported by CARB-X. Also offers robotic bacteriophage discovery and synthetic biology to engineer phage products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Locus Biosciences company profile →
NYtor
HQ: The Netherlands
Website
- Description: Provider of biotechnology research solutions, offering quantitative PCR, molecular beacons, and antibiotic resistance services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NYtor company profile →
HomeDNA
HQ: United States
Website
- Description: Provider of a home paternity test kit; a pharmaceutical firm.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HomeDNA company profile →
AnimalBiome
HQ: United States
Website
- Description: Provider of microbiome-focused pet health solutions for dogs and cats, including gut health test kits for stool-based microbiome analysis, gut restore supplements with healthy bacteria, gut maintenance products with prebiotics and probiotics, oral health products with prebiotic action, a State of the Gut report with dietary and exercise recommendations, and microbiome research partnerships.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AnimalBiome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for IMGM Laboratories
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to IMGM Laboratories
2.2 - Growth funds investing in similar companies to IMGM Laboratories
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for IMGM Laboratories
4.2 - Public trading comparable groups for IMGM Laboratories
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →